Startups
ABOLOGIX develops novel therapeutics in oncology. The company´s lead program is a monoclonal antibody (code-named H-225) for the treatment of several sub-types of non-Hodgkin´s lymphoma (NHL), specifically Mantle Cell Lymphoma (MCL), a disease of very poor prognosis. H-225 blocks the function of JAM-C, a cell adhesion molecule involved in the transmigration of lymphocytes out of the tissues and into the blood stream. In preclinical in vivo animal models ABOLOGIX has shown that treatment with H-225 leads to a a dramatic increase in overall survival. The next steps are the humanization of H-225 (in progress) and testing the potential of the molecule in Phase I/IIa clinical trials. We then intend to license / sell H-225 to a large pharma company for further development and commercialization
Overview
Location
Switzerland, Geneva, Plan-les-Ouates
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 27, 2021 | Abologix wins Venture Kick finale | B-cell lymphocytes are white blood cells circulating in the bloodstream: They play a critical role in the fight against infections and cancer. However, B-cell lymphocytes can become cancerous and transform into cancer cells, called lymphoma... |
| Feb 2, 2021 | Swiss startups braced for a virtual bootcamp in Boston and New York | The startup bootcamp offers Swiss startups the opportunity to immerse themselves into the vibrant startup ecosystems of Boston or New York in order to prepare their US market entry or to validate their product-market fit before they decide ... |
| Feb 2, 2021 | Swiss startups braced for a virtual bootcamp in Boston and New York | |
| Sep 14, 2020 | Strong Swiss delegation at Bio Europe | |
| Sep 14, 2020 | Strong Swiss delegation at Bio Europe | Bio Europe, Europe’s largest platform designed for companies in the biotech and pharma sectors to meet and forge partnerships. Last year, the event hosted more than 4’400 visitors from 61 countries and 2300 companies. Over 27’300 one-to-one... |
| Apr 1, 2019 | Swiss Biotech Day to shed light on 13 emerging startups |
Reviews 0
FAQ about Abologix Sàrl
What has the press written about Abologix Sàrl?
Parsers VC has collected 7 articles mentioning Abologix Sàrl, among them “Abologix wins Venture Kick finale” (May 27, 2021) and “Swiss startups braced for a virtual bootcamp in Boston and New York” (Feb 2, 2021).
Is Abologix Sàrl still active?
Yes, Abologix Sàrl is active; its latest activity on Parsers VC dates from May 27, 2021.